Provided by Tiger Trade Technology Pte. Ltd.

X4 Pharmaceuticals Inc

2.91
+0.12004.30%
Post-market: 2.960.0497+1.71%17:21 EDT
Volume:541.20K
Turnover:1.58M
Market Cap:288.52M
PE:-3.28
High:2.97
Open:2.83
Low:2.82
Close:2.79
52wk High:4.83
52wk Low:2.70
Shares:99.15M
Float Shares:62.35M
Volume Ratio:0.77
T/O Rate:0.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.8867
EPS(LYR):-1.8726
ROE:-113.08%
ROA:-28.15%
PB:1.86
PE(LYR):-1.55

Loading ...

X4 Pharmaceuticals Issues Inducement Stock Options for 12,000 Shares at $3.98 Each

Reuters
·
Aug 04

X4 Pharmaceuticals Inc : Wells Fargo Initiates Coverage with Overweight Rating; Price Target $11

THOMSON REUTERS
·
Jul 10

X4 Pharmaceuticals Issues Inducement Stock Options for 750,000 Shares at $4.03 Each

Reuters
·
Jul 08

X4 Pharmaceuticals Director Kelly Gold Files Initial Beneficial Ownership Statement

Reuters
·
Jul 02

Press Release: X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to Its Board of Directors

Dow Jones
·
Jul 01

X4 Pharmaceuticals Initiated at Outperform by Leerink Partners

Dow Jones
·
Jun 02

X4 Pharmaceuticals initiated with an Outperform at Leerink

TIPRANKS
·
Jun 02

X4 Pharmaceuticals Inc : Leerink Partners Initiates Coverage With Outperform Rating; Price Target $12

THOMSON REUTERS
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

BRIEF-X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule

Reuters
·
Jun 02

X4 Pharmaceuticals grants 160,000 inducement stock options priced at $4.31 per share

Reuters
·
Jun 02

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 02

X4 Pharma to present at Jefferies Global Healthcare Conference

Reuters
·
May 27

X4 Pharmaceuticals corrects director nominee name in amended 8-K filing

Reuters
·
May 14

X4 Pharmaceuticals shareholders approved amended 2017 equity incentive plan share increase

Reuters
·
May 13

BRIEF-X4 Pharmaceuticals Inc - May Offer Up To $300 Million Of Common Stock, Preferred Stock, Debt Securities, Warrants, And/Or Units - SEC Filing

Reuters
·
May 07

X4 Pharmaceuticals Inc - May Offer up to $300 Mln of Common Stock, Preferred Stock, Debt Securities, Warrants, and/or Units - SEC Filing

THOMSON REUTERS
·
May 07

X4 Pharmaceuticals net loss widens to $20.2 million in Q1 FY26; revenue drops to $2.7 million

Reuters
·
May 06

BRIEF-X4 Pharmaceuticals Q1 EPS USD -0.16

Reuters
·
May 06

X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 06